Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linperlisib + cyclophosphamide + prednisone + thalidomide
- Development stage
- Phase 2
- Lead developer
- Yingli Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Linperlisib + CPT is a combination therapeutic regimen consisting of linperlisib, a selective small molecule inhibitor of the delta isoform of phosphatidylinositol 3-kinase (PI3Kδ), and the CPT regimen, which includes cyclophosphamide, prednisone, and thalidomide. Linperlisib, developed by Shanghai Yingli Pharmaceutical, targets the PI3Kδ pathway, which is critical for the proliferation and survival of malignant B-cells and T-cells. Cyclophosphamide acts as an alkylating agent that cross-links DNA, while prednisone is a corticosteroid with lympholytic activity. Thalidomide provides immunomodulatory effects by targeting cereblon (CRBN) and inhibiting angiogenesis. This specific combination is being evaluated in a multicenter Phase 2 clinical trial sponsored by The First Affiliated Hospital with Nanjing Medical University for the treatment of various relapsed or refractory non-Hodgkin lymphoma (NHL) subtypes, including follicular lymphoma, peripheral T-cell lymphoma, NK/T-cell lymphoma, chronic lymphocytic leukemia, marginal zone lymphoma, and mantle cell lymphoma.
- Brand names
- Linpuzhi
- Other names
- Linperlisib + CPT regimenLinperlisib + CPT
02
Targets
CRBN (Cereblon)DNAGR (Glucocorticoid receptor)PIK3CD (Phosphatidylinositol 3-kinase delta)
Beyond the preview
Go deeper on linperlisib + cyclophosphamide + prednisone + thalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linperlisib + cyclophosphamide + prednisone + thalidomide.